3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
449
Lymphoma
55
Recurrence
45
Neoplasms, Plasma Cell
35
Immunoglobulin Light-chain Amyloidosis
34
Hematologic Neoplasms
34
Smoldering Multiple Myeloma
28
Lymphoma, Non-Hodgkin
27
Leukemia, Myeloid, Acute
22
Leukemia, Lymphocytic, Chronic, B-Cell
21
Neoplasms
20
Precursor Cell Lymphoblastic Leukemia-Lymphoma
19
Hodgkin Disease
18
Myelodysplastic Syndromes
17
Monoclonal Gammopathy of Undetermined Significance
13
Leukemia
12
Waldenstrom Macroglobulinemia
11
Lymphoma, Mantle-Cell
11
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
11
Breast Neoplasms
11
Prostatic Neoplasms
10
Lymphoma, Large B-Cell, Diffuse
10
Paraproteinemias
9
Ovarian Neoplasms
9
Amyloidosis
9
Lung Neoplasms
8
Leukemia, Plasma Cell
8
Primary Myelofibrosis
7
Melanoma
7
Lymphoma, Follicular
7
Interventions
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Amyloid Neuropathies, Familial
×
Plasma cell
×
90 days
×
Clear all
NCT05184088
2026-06-02
CArdiag
Lantheus Biosciences Ltd.
Phase 3
Completed
244 enrolled
NCT03431896
2026-03-12
MED-hATTR
The Cleveland Clinic
Completed
37 enrolled